X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Ovarian Cancer Type Gets An Effective Targeted Drug Combo

    New Singapore Therapy For Antibiotic Resistant Lung Issues

    Diosynvax – A Needle-Free Revolution In COVID-19 Vaccination

    Genome Analysis Offers New Hope For Severe Skin Condition

    Vorasidenib – A Potential Game-Changer In Glioma Treatment

    Adapting To The Changing Virus By Enhancing Vaccine Immunity

    UK Boosts Life Sciences Sector With £650 Million Funding

    UK Boosts Life Sciences Sector With £650 Million Funding

    Indian Pharma Business May Increase 8-11%, Predicts Alkem

    Chinese Market Regulator Fines Two Monopolistic Pharma Firms

    Enhancing Patient Care In The UK Through Recognition Routes

    Enhancing Patient Care In The UK Through Recognition Routes

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Ovarian Cancer Type Gets An Effective Targeted Drug Combo

    New Singapore Therapy For Antibiotic Resistant Lung Issues

    Diosynvax – A Needle-Free Revolution In COVID-19 Vaccination

    Genome Analysis Offers New Hope For Severe Skin Condition

    Vorasidenib – A Potential Game-Changer In Glioma Treatment

    Adapting To The Changing Virus By Enhancing Vaccine Immunity

    UK Boosts Life Sciences Sector With £650 Million Funding

    UK Boosts Life Sciences Sector With £650 Million Funding

    Indian Pharma Business May Increase 8-11%, Predicts Alkem

    Chinese Market Regulator Fines Two Monopolistic Pharma Firms

    Enhancing Patient Care In The UK Through Recognition Routes

    Enhancing Patient Care In The UK Through Recognition Routes

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development

Ovarian Cancer Type Gets An Effective Targeted Drug Combo

Content Team by Content Team
8th June 2023
in Drug Development, News

A targeted drug combination for patients suffering from an ovarian cancer type can be nearly twice as effective as the next-best treatment, according to preliminary results from a Phase II study.

Researchers opine that these results, which happen to be presented at the 2023 American Society of Clinical Oncology annual meeting, will go on to lead to a new choice for patients with advanced low-grade serous ovarian cancer- LGSOC, a rare form of the illness with a poor response rate to the existing treatments.

This international RAMP-201 study, which happens to be led by The Institute of Cancer Research, London, UK, and The Royal Marsden NHS Foundation Trust, tested avutometinib alone and in combination with defactinib across 29 patients who have LGSOC.

It is worth noting that the available treatment options for patients who have advanced LGSOC across the UK are limited at present to just chemotherapy as well as hormone therapy, with rates of response ranging from 0–14%.

In addition to the standard treatment. LGSOC patients across England can go on to access trametinib, which is a focused treatment through the Cancer Drug Fund and has a response rate of 26%.

Clinical Trial Results of RAMP-201

As per these results, 45% of the patients who happened to be treated with avutometinib teamed with defactinib witnessed their tumours shrink quite dramatically. Apparently, the responses when it comes to the combination of the drug were specifically promising in those areas that had a KRAS mutation, with 60% of the patients getting to experience quite a prominent shrinkage. That said, 29% of the patients without the mutation also went on to have a response, which was very encouraging.

It is well worth noting that the patients who happened to be previously treated with varied kinds of targeted therapies, such as MEK inhibitors, also witnessed the shrinkage of the tumours after the treatment with the combination drug.

Avutometinib happens to be a dual RAF and MEK inhibitor, which goes on to block certain proteins that aid in controlling the growth of cancer as well as its survival. Certain studies have gone on to show that the drug can very well turn out to be ineffective with time as tumours go on to create treatment resistance. Although, when teamed with defactinib, treatment happens to be four times more effective than just avutometinib.

RAMP-201 goes on to follow the Phase 1 FRAME trial that tested defactinib and avutometinib in advanced LGSOC. It was practised by the researchers from the Oak Foundation Drug Development Unit, based out of the Royal Marsden NHS Foundation Trust and the Institute of Cancer Research in London.

Notably, the inferences from the FRAME indicate the fact that this patient group happens to live an average of 23 months after the treatment with this combination of drugs before there is once again a progression in the cancer.

Dr. Susana Banerjee, who happens to be the global lead investigator of the study, opines that low-grade serous ovarian cancer in no way responds the way it should to the current line of treatments, and therefore these inferences can very well be a representation of the prominent breakthrough when it comes to taking care of these diseases. She added that they are indeed hopeful that this drug mixture will one day go on to become a benchmark of care for women suffering from low-grade serous ovarian cancer.

Previous Post

New Singapore Therapy For Antibiotic Resistant Lung Issues

Related Posts

News

New Singapore Therapy For Antibiotic Resistant Lung Issues

8th June 2023
Drug Development

Diosynvax – A Needle-Free Revolution In COVID-19 Vaccination

7th June 2023
Drug Development

Genome Analysis Offers New Hope For Severe Skin Condition

7th June 2023
News

Vorasidenib – A Potential Game-Changer In Glioma Treatment

7th June 2023
Facilities & Operation

Advancing RNA Therapeutics With UK Drug Delivery Centre

6th June 2023
United Cargo Meets Growing Demand for Pharmaceuticals with New TempControl Containers
News

DoKaSch Temperature Solutions appoints Sales & Business Development Manager for China

3rd June 2023

Latest News

Drug Development

Ovarian Cancer Type Gets An Effective Targeted Drug Combo

8th June 2023
News

New Singapore Therapy For Antibiotic Resistant Lung Issues

8th June 2023
Drug Development

Diosynvax – A Needle-Free Revolution In COVID-19 Vaccination

7th June 2023
Drug Development

Genome Analysis Offers New Hope For Severe Skin Condition

7th June 2023
News

Vorasidenib – A Potential Game-Changer In Glioma Treatment

7th June 2023
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In